X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NPI-001 (AT-001 ) combats rare hereditary forms of dementia. Currently, it is being evaluated in the IND enabling stage for the treatment of Hereditary Cystatin C Amyloid Angiopathy.
Lead Product(s): Grapiprant
Therapeutic Area: Genetic Disease Product Name: NPI-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arctic Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
NPI-002 is a novel, differentiated, slow-release, small molecule being developed to slow cataract progression. For the treatment of cataract, a sterile intravitreal implant containing NPI-002 has been developed, along with a precision delivery system.
Lead Product(s): NPI-002
Therapeutic Area: Ophthalmology Product Name: NPI-002
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
NPI-001 is an oral, small molecule, proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) tablets being developed in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH).
Lead Product(s): N-acetylcysteine Amide
Therapeutic Area: Genetic Disease Product Name: NPI-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
NPI-001 is a differentiated, purified, prescription-quality, GMP-grade N-acetylcysteine amide (NACA) being developed to treat a broad set of diseases and conditions associated with oxidative stress and reduced glutathione levels.
Lead Product(s): N-acetylcysteine Amide
Therapeutic Area: Rare Diseases and Disorders Product Name: NPI-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arctic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2022
Details:
Proceeds from the financing will be used to support the advancement of Nacuity’s clinical trials for NPI-001 and NPI-002 through proof of concept, as well as for general operations.
Lead Product(s): NPI-001
Therapeutic Area: Genetic Disease Product Name: NPI-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Foundation Fighting Blindness
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 15, 2022
Details:
Nanoform and Nacuity have signed a Technology Proof of Concept Agreement. This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.
Lead Product(s): NPI-001
Therapeutic Area: Ophthalmology Product Name: NPI-001
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Nanoform
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
